Donenberg Phillip B. 4
4 · Sensei Biotherapeutics, Inc. · Filed Apr 14, 2026
Research Summary
AI-generated summary of this filing
Sensei Biotherapeutics (SNSE) Director Donenberg Receives Option Award
What Happened
Phillip B. Donenberg, a director of Sensei Biotherapeutics (SNSE), received a supplemental option grant of 23,100 shares on April 10, 2026. The grant was reported on a Form 4 filed April 14, 2026. The award was recorded at $0.00 (derivative grant) and is part of his non-employee director compensation rather than an open-market purchase or sale.
Key Details
- Transaction date: April 10, 2026; Form 4 filed April 14, 2026 (timely).
- Transaction type: Grant/award of stock options (derivative).
- Shares/options granted: 23,100 supplemental shares; combined with a prior February 2026 grant of 1,900 shares, this aligns the total initial director option grant to 25,000 shares (per amended policy).
- Price recorded: $0.00 (award/option grant).
- Vesting: Options vest in 36 equal monthly installments over three years; fully vested on April 10, 2029, subject to continued service.
- Shares owned after transaction: Not specified in the filing.
- Footnotes: F1 explains this is a supplemental grant to meet the amended director comp policy; F2 details the monthly 3-year vesting schedule.
- Remarks: Exhibit 24 (Power of Attorney) attached.
Context
This was a compensatory option award to a non-employee director under an amended director compensation policy (initial director grant set to 25,000 shares). It is a derivative grant that vests over time and does not represent an immediate purchase or sale of common stock. Such routine director awards are common and reflect compensation, not necessarily a personal trading signal.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1][F2]2026-04-10+23,100→ 23,100 totalExercise: $29.89Exp: 2036-04-09→ Common Stock (23,100 underlying)
Footnotes (2)
- [F1]Represents a supplemental option grant to align the Reporting Person's total initial director option grant with the Company's non-employee director compensation policy, which was amended on April 10, 2026 to provide for an initial option grant of 25,000 shares to new directors. The Reporting Person previously received an initial grant of 1,900 shares in February 2026; this supplemental grant of 23,100 shares reflects the difference.
- [F2]The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or April 10, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.